ACCESSWIRE
13 May 2022, 22:37 GMT+10
MILLBROOK, NY / ACCESSWIRE / May 13, 2022 / Bexil Corporation (Stock Symbol:BXLC) ('Bexil' or the 'Company') today reported its financial results for the first quarter ended March 31, 2022.
For the three months ended March 31, 2022, Bexil recorded net income attributable to Bexil shareholders of approximately $0.14 million or $0.19 of diluted earnings per share, compared to net income attributable to Bexil shareholders of approximately $2.19 million or $2.65 of diluted earnings per share for the three months ended March 31, 2021.
Generally Accepted Accounting Principles ('GAAP') require that the Company include the changes in unrealized gains/losses of its equity security investments in net income. Such investment gains/losses include losses of $0.30 million in the three months ended March 31, 2022 and gains of $1.86 million in the three months ended March 31, 2021. The amount of investment gains/losses in any given period is usually meaningless and delivers figures for net earnings per share that can be extremely misleading to investors who have little or no knowledge of accounting rules, as noted in a recent Berkshire Hathaway press release.
The Company's book value per share attributable to Bexil shareholders at March 31, 2022 was $36.25, based on shareholders' equity attributable to Bexil shareholders of approximately $27.3 million and 753,228 shares issued and outstanding. The Company's book value per share attributable to Bexil shareholders at March 31, 2021 was $29.75, based on shareholders' equity attributable to Bexil shareholders of approximately $24.7 million and 830,577 shares issued and outstanding.
The limited information above in this press release is not adequate for making an informed investment judgment, and we urge stockholders and investors to read the Company's unaudited quarterly report for the quarterly period ended March 31, 2022, which is available at www.Bexil.com appended to the copy of this press release and at www.otcmarkets.com under the Company's stock symbol.
About Bexil Corporation
The objective of Bexil Corporation, a holding company, is to increase book value per share over time for the benefit of its shareholders. The Company is primarily engaged through a wholly owned subsidiary, Bexil Advisers LLC, in investment management. Bexil Advisers is a registered investment adviser and the investment manager to Dividend and Income Fund, a closed end fund (Stock Symbol:DNIF) (NAV Symbol:XDNIX). To learn more about Bexil, including Rule 15c2-11 information, please visit www.Bexil.com.
Safe Harbor Note
This release may contain certain 'forward looking statements' within the meaning of federal securities laws including, but not limited to the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Bexil, which may cause the Company's actual results to be materially different from those expressed or implied by such statements. The Company may also make additional forward looking statements from time to time. All such subsequent forward looking statements, whether written or oral, by the Company or on its behalf, are also expressly qualified by these cautionary statements. Investors should carefully consider the risks, uncertainties, and other factors, together with the information included in the Company's Annual Report, at http://www.bexil.com/cautionary-language.html, and similar information. All forward looking statements made herein are only made as of the date of this release, and the Company undertakes no obligation to publicly update such forward looking statements to reflect subsequent events or circumstances.
The Company views book value per share, a non-GAAP financial measure, as an important indicator of financial performance. Presented in conjunction with other financial information, the combined presentation can enhance an investor's understanding of the Company's underlying financial condition and results from operations. The definition of book value as presented in this press release is shareholders' equity attributable to Bexil shareholders divided by currently issued and outstanding shares.
CONTACT:
Thomas O'Malley
Chief Financial Officer
1-212-785-0900
tomalley@bexil.com
www.Bexil.com
SOURCE: Bexil Corporation
Get a daily dose of Baltimore Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Baltimore Star.
More InformationDOLNI MORAVA, Czech Republic: The world's longest pedestrian suspension bridge has opened at a mountain resort in the Czech Republic. ...
SHAN STATE, Myanmar - According to an officer who participated in the assault, two local defense forces have destroyed a ...
TUNIS, Tunisia - The Tunisian navy said Saturday that it rescued 81 migrants, including 32 Bangladeshis, sailing from Libya to ...
ST. PETERSBURG, Florida: - A nearly $1 billion settlement has been agreed upon in a lawsuit brought by families of ...
The suspect is an 18-year-old white man heavily armed with tactical gear and a helmet, said Buffalo Police Commissioner Joseph ...
SAN JOSE, Costa Rica: President Rodrigo Chaves, who was sworn in as president on May 8, has declared a state ...
NEW YORK, New York - Weak economic news out of China undermined stocks on Wall Street on Monday. The major ...
ATLANTA, Georgia: Mercedes-Benz USA has requested drivers to stop driving some of their autos immediately due to braking problems.The announcement ...
KARACHI, Pakistan - The U.S. dollar climbed past Rs194 in the interbank market in Pakistan on Monday as analysts expressed ...
ROME, Italy: Italy has announced plans to sell state-owned ITA Airways, the successor to Alitalia, by the end of June, ...
SYDNEY, NSW, Australia - Stocks struggled for direction in Asia on Monday. Early gains evaporated later in the data, although ...
BEIJING, China: China's Green Valley Pharmaceutical company has prematurely ended an FDA approved study on its GV-971 to treat mild ...